CD274 and neoplasm: This interpretation is supported by the observation that many of the features that predict long-term PFS to ICI-mono, such as PD-L1, are the same as those that predict long-term PFS to ICI-chemo, indicating that patients who experience long-term benefits to ICIs do so because of their particular tumor-immune features rather than from the inclusion of chemotherapy.